ORAGENICS INC (OGEN) Form 8-K — Aug 28, 2026
Oragenics received a deficiency letter from NYSE American on August 26, 2026, stating the company no longer meets the exchange's continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide. Shares remain listed and trading as OGEN with no immediate delisting impact, but the ticker now carries a '.BC' below-compliance designation. The company reported stockholders' equity of $3.7 million at June 30, 2026, below the $4 million and $6 million thresholds required by the exchange, after net losses in each of its five most recent fiscal years.
Key figures
- Stockholders equity
- $3.7 million at June 30, 2026
- Ind submission target
- end of 2026
- Active australian sites
- 3
- Compliance plan deadline
- September 25, 2026
- Ticker designation added
- .BC (below compliance)
- Equity requirement 1003aii
- $4 million
- Phase2a participants dosed
- 9
- Regain compliance deadline
- February 25, 2028
- Equity requirement 1003aiii
- $6 million
- Consecutive fiscal year net losses
- 5
Price after filing
Close on the filing date to close N calendar days later (from $0.52). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.